Your search history is turned on.
Date: May 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
FORM 52-109F2 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jose DaRocha, Chief Financial Officer of Crescita Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Crescita Therapeutics Inc. (the issuer) for the interim perio...
FORM 52-109F2 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Serge Verreault, President & Chief Executive Officer of Crescita Therapeutics Inc., certify the-following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Crescita Therapeutics Inc. (the issuer) fo...
Managements Discussion & Analysis First Quarter 2024 2 | P a g e Crescita Therapeutics Inc. Managements Discussion & Analysis First Quarter 2024 Managements Discussion and Analysis May 7, 2024 Basis of Pre...
CTX_Q1-2024 FS_FINAL Crescita Therapeutics Inc. Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2024 and 2023 (unaudited) 2 | P a g e Crescita Therapeutics Inc. Condensed Consolidat...
CTX_Q1-2024 Results PR_FINAL 1Please refer to the Non-IFRS Financial Measures section of this press release. Crescita Reports First Quarter 2024 Results Laval, QC, May 8, 2024 Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (Crescita or the Company), a growth-oriented, innovation-driven Canadian commercial dermatology company, today r...
Date: April 23, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 5, 2024 NOTICE AND ACCESS NOTIFICATION TO SHAREHOLDERS You are receiving this notification as Crescita Therapeutics Inc. (the Corporation) has elected to use the notice and access system for delivery of meeting materials to its shareholders in respect of its annual general and special...
PROXY SOLICITED BY THE MANAGEMENT OF CRESCITA THERAPEUTICS INC. For use at the Annual General and Special Meeting of Shareholders to be held on Wednesday, June 5, 2024. The undersigned shareholder of CRESCITA THERAPEUTICS INC. (the Corporation) hereby appoints Serge Verreault, President and CEO of the Corporation, or, instead of him, ____________________________...
2023 Annual Report Managements Discussion and Analysis March 12, 2024 Basis of Presentation This Managements Discussion and Analysis of the financial position and results of operations (MD&A) is the responsibility of management and has been reviewed and approved by Crescitas board of directors (the Board of Directors). This MD&A ha...
Notice of Annual General and Special Meeting of Shareholders and Management Information Circular TO BE HELD WEDNESDAY, JUNE 5, 2024 AT 9:00 A.M. (ET) at 2805 PLACE LOUIS-R-RENAUD, LAVAL, QUBEC RECORD DATE: MONDAY, APRIL 8, 2024 PROXY CUT-OFF DATE AND TIME NO LATER THAN 5:00 P.M. (ET) ON MONDAY, JUNE 3, 2024 2 ...
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General and Special Meeting of Shareholders (the Meeting) of CRESCITA THERAPEUTICS INC. (the Corporation or Crescita) will be held on Wednesday, June 5, 2024 at 9:00 a.m. (ET) at 2805 Place Louis-R-Renaud, Laval, Qubec for the following purposes: (...